Agostinho Carvalho graduated in 2003 in Biology from the University of Minho and received a PhD in Health Sciences from the same University in 2008. Between 2009 and 2012, he developed postdoctoral studies on the genetic basis of susceptibility to fungal infection at the Life and Health Sciences Research Institute (ICVS) of the University of Minho, and the University of Perugia, Italy. In 2012, he became an Assistant Researcher at the Department of Experimental Medicine of the University of Perugia, where he further developed his interests in fungal immunology and immunogenetics until 2014. Later that year, he became an Assistant Researcher and returned to ICVS, where he consolidated his research team. Since 2019, he has been a Principal Investigator (with Habilitation since 2023) at ICVS. He is the elected Coordinator of the Immunobiology of Inflammatory and Infectious Diseases team, which comprises more than 30 members, including 11 PhD researchers. In 2019, he was appointed Vice-Director of ICVS, a position he held until 2025, when he assumed the role of Vice-Dean for Research at the School of Medicine. His research activity is focused on the elucidation of the effects of interindividual genetic variation on molecular and cellular processes of immunity and inflammation, and the translation of this information into new and personalized approaches for the prognosis, diagnosis, and therapy of infectious and inflammatory diseases. These aims are being addressed by a multidisciplinary team that combines basic scientists and clinical experts with different degrees of specialization, and that resorts to advanced cellular and animal models of disease and human patients enrolled in national and international consortia. The team is also engaged in collaborations with several international labs on immunology, functional genomics, and the biology of infectious and inflammatory diseases. He has published over 160 papers in international peer-reviewed journals (>9,600 citations and h-index=47, ISI Web of Knowledge; March 2026), 1 book and 9 book chapters, and a patent on fungal diagnostics. Selected recent publications include senior authorship of papers in Lancet Respir Med, Nat Microbiol, Am J Respir Crit Care Med, N Engl J Med, and Nat Commun, besides collaborations in Nature, Cell Genomics, Lancet Microbe, Sci Transl Med, Cell Host Microbe, and Nat Microbiol. He has been supported by several funding agencies, e.g., H2020, "la Caixa" Foundation, Fundação para a Ciência e a Tecnologia (FCT), the Ann Theodore Foundation, and contracts with the industry, e.g., Gilead, Mérieux. He has supervised 11 postdoctoral researchers and 12 PhD students, besides multiple MSc and undergraduate students. He is an editorial board member for PLoS Pathogens, Journal of Infectious Diseases, Infection and Immunity and Microbiology Spectrum. He has been an ad-hoc reviewer for more than 70 journals and several funding agencies, including the European Commission (e.g., ERC, H2020, MSCA), Wellcome Trust, Agence Nationale de la Recherche (ANR), Ministero dell'Istruzione e del Merito (MIUR), Israel Science Foundation (ISF), and FCT. Because of his contributions to the field, he has received over 70 invitations to speak/chair at established international meetings, and several awards, including the Jon J. van Rood award for outstanding contributions in immunogenetics. He is an elected Fellow of the European Confederation of Medical Mycology (ECMM).